H-Index: 33. Total citations (Scopus & Web of Science/Publons): 3700. Citations (Scopus): 2017: 204, 2018:187, 2019:208, 2020:232, 2021:306, 2022: 282

62 scientific articles: 50 Q1 (81%); 11 Q2 (17.4%), 1 Q3 (1.6%), and 11% (7) in D1.

Last 10 years (2013-23): 30 scientific articles (26 in Q1, 4 in Q2) and 1st/last author (15)

Last 5 years (2019-23): 15 scientific articles (13 in Q1, 2 in Q2; 4 in D1) and 1st/last author (9)

Research Accreditation (CNEAI): 1996-01, 2002-07, 2008-13, 2014-19.  Teaching Accreditation (ANECA): 1997-01, 2002-6, 2007-11, 2012-16, 2017-21. Research Accreditation (AQU/Generalitat Catalunya): 1996-01, 2002-07, 2008-13, 2014-19. Accrediation Full Professor (ANECA): 2018.

Dr. Saura obtained his Ph.D. in Chemistry/Biochemistry and Molecular Biology from University of Barcelona, and then performed postdoctoral training at the Dpt of Pathology of the Johns Hopkins University and Department of Neurobiology at the University of Chicago (1998-99). In 2000, he was appointed Instructor Professor at the Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School (USA). Under Prof. J. Shen’s mentoring, Dr. Saura investigated cellular and molecular mechanisms underlying memory loss and neurodegeneration in novel transgenic and knockout mouse models of Alzheimer’s disease (AD), studies published as first author papers in Neuron (2001,2004) and J. Neurosci (2005).  In 2004, Dr. Saura was recruited as a Ramón y Cajal Research Fellow at the Universitat Autònoma de Barcelona, where he is currently Associate Professor at the Dpt Biochemistry and Molecular Biology. Dr. Saura’s lab (www.sauralab.com) at Institut de Neurociències-UAB (https://inc.uab.cat/en) is recognized as Excellent research group from Generalitat de Catalunya (2021 SGR0142) and is a member of the Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)-Instituto Carlos III since 2007.

Dr. Saura lab’s scientific interest is focused on cellular and molecular mechanisms of brain function and dysfunction in cognitive disorders, particularly Alzheimer’s disease (AD). His lab uses novel transcriptomic, brain imaging and chemogenetic approaches  to understand the transcriptomic mechanisms underlying synaptic changes in neurodegeneration and AD. Saura lab’s studies have been published in Neuron, Biol Psychiatry, eLife, J. Neurosci, Small, Sci. Reports, and reviewed in seminal reviews in Front Neurosci (2015, 2020), Trends Neurosci (2017), Biol Psychiatry (2019), and Semin Cell Dev Biol (2023). Dr. Saura has coauthored 64 peer-reviewed manuscripts with 3700 citations (Scopus/Web of Science/Publons; 300 citations/year in 2021 and 2022),and is Review Editor for Front Mol Neurosci and Front Neurogenetics.

Dr. Saura has coordinated several national and international research projects (3 million € last 10 years) and collaborates with national and international funding agencies and scientific journals. Dr. Saura acts as grant reviewer for the Alzheimer’s Association, Instituto Carlos III, Spanish Research Agency (AEI), Agence Nationale de la Recherche (ANR)- France, Romanian National Research Council, Fundación Ikerbasque, Junta de Andalucía, and has participated as pannelist of Ramón y Cajal Program (2017, 2021 vice-president), and Biomedicine Research Grants (2012, 2015, 2017; Manager: 2019, 2020; President: 2021, 2022, 2023). Dr. C. Saura was member of the Directive Board of the Institut de Neurociències-UAB (2009-17), Scientific Advisor Committee of Araclon Biotech SL (Grifols; 2009-11), Directive Board/Treasurer of the Sociedad Española de Neurociencia  (2015-19), and is Coordinator of the Neurobiology Section-Societat Catalana de Biologia (2015-23). Dr. Saura was appointed Manager (2018-19) and Coordinator (2020-23) of the Biomedicine/Nervous System Diseases Grant Program at División de Coordinación, Evaluación y Seguimiento Científico Técnico-AEI.